Prime Medicine (PRME) Other Non-Current Liabilities (2024 - 2026)

Prime Medicine (PRME) has 3 years of Other Non-Current Liabilities data on file, last reported at $18.0 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 50.0% year-over-year to $18.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.0 million (up 50.0% YoY) and the FY2025 annual result came in at $18.0 million, up 200.0% from the prior year.
• Other Non-Current Liabilities was little changed at $18.0 million in Q1 2026, from $18.0 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $18.0 million in Q3 2025 to a low of $6.0 million in Q1 2024.
• A 3-year average of $11.3 million and a median of $12.0 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2025 — Other Non-Current Liabilities surged 200.0% — and 2026, when it jumped 50.0%.
• Tracing PRME's Other Non-Current Liabilities over 3 years: stood at $6.0 million in 2024, then surged by 200.0% to $18.0 million in 2025, then changed by 0.0% to $18.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $18.0 million (Q1 2026), $18.0 million (Q4 2025), and $18.0 million (Q3 2025), per Business Quant data.